Sort by 'likes'
Using Clinical Data to Determine Treatments in Myeloma
Using Clinical Trial Data to Determine Treatment Options, has been successfully implemented by Dr. McCarthy and team and here he discusses the various preclinical new drug developments for myeloma treatment
Nonsecretory Multiple Myeloma: New Options in Assessment and Treatment
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component…
Myeloma with The MMRF
Towards the end of last year in 2013, MMRF rolled out three important cancer research initiatives - big data and genomic sequencing, open access by sharing research data, and empowering patients to find clinical trials that are best for them…
Cancer Legal Resource Center on Myeloma Support Group
Attorney Anya Prince from Cancer Legal Resource Center (CLRC) joins our myeloma support group leaders, Gary Petersen and Cynthia Chmielewski on On-Air Myeloma Support Group Meet.
High Risk Multiple Myeloma Survival w/ Dr. Rafael Fonseca of Mayo Clinic
What does high-risk means in a patient who is diagnosed with multiple myeloma? What are the markers that determine the most common sub-category of high-risk myeloma? What are the best treatments for high-risk disease and what are the most promising…